
Opinion|Videos|April 14, 2025
Evaluating Ruxolitinib In An 18-Month Retrospective Claims Analysis
Author(s)Gary M. Owens, MD , Lawrence Eichenfield, MD
Panelists discuss how an 18-month retrospective claims analysis evaluated ruxolitinib's real-world effectiveness in atopic dermatitis, demonstrating sustained disease control, reduced healthcare utilization, decreased steroid dependency, improved medication adherence, and consistent safety outcomes across diverse patient demographics and disease severities compared to conventional treatments.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The biosimilars market is projected to nearly double — here's where the growth is coming from
2
Journavx helped most patients avoid opioids after surgery, a recent study found
3
Endometriosis increases the risk of Type 2 diabetes
4
Cholinergic urticaria: Hives caused by heat and what can be done about it
5














